Einloggen

Thematische Bibliographien / Small Cell Lung Cancer / Zeitschriftenartikel

Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: Small Cell Lung Cancer.

Zeitschriftenartikel zum Thema „Small Cell Lung Cancer“

Autor: Grafiati

Veröffentlicht am 4. Juni 2021

Zuletzt aktualisiert am 9. Juni 2025

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Small Cell Lung Cancer" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.

1

Greschuchna, D. "Surgical Treatment of Small Cell Lung Cancer." Journal of the Japanese Association for Chest Surgery 3, no. 2 (1989): 169. http://dx.doi.org/10.2995/jacsurg1987.3.2_169.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Skenduli, Ilir, and Perlat Kapisyzi. "Surgery for Non Small Cell Lung Cancer - A Systematic Review." International Journal of Science and Research (IJSR) 11, no. 5 (May 5, 2022): 1551–56. http://dx.doi.org/10.21275/sr22518021202.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

_, _. "Small Cell Lung Cancer." Journal of the National Comprehensive Cancer Network 6, no. 3 (March 2008): 294. http://dx.doi.org/10.6004/jnccn.2008.0025.

Der volle Inhalt der Quelle

Annotation:

Small cell lung cancer (SCLC) accounts for 15% of lung cancers. Nearly all cases of SCLC are attributable to cigarette smoking, and the remaining cases are presumably caused by environmental or genetic factors. Compared with non-small cell lung cancer, SCLC generally has a more rapid doubling time, a higher growth fraction, and earlier development of widespread metastases. SCLC is highly sensitive to initial chemotherapy and radiotherapy, but most patients eventually die from recurrent disease. These guidelines detail the management of SCLC from initial diagnosis and staging through treatment, and include information on supportive and palliative care. Important updates to the 2008 version include refined categories for performance status and the addition of topotecan as an option for patients who experience relapse. For the most recent version of the guidelines, please visit NCCN.org

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Hellriegel, H. "ADVANCED NON-SMALL-CELL LUNG CANCER. THE SIGNIFICANCE OF PERSONALIZED THERAPY." Siberian Medical Review, no. 6 (2017): 6–12. http://dx.doi.org/10.20333/2500136-2017-6-12.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Klaus-Peter, K. "ADVANCED NON-SMALL-CELL LUNG CANCER. THE SIGNIFICANCE OF PERSONALIZED THERAPY." Siberian Medical Review, no. 6 (2017): 6–12. http://dx.doi.org/10.20333/2500136-2017-6-6-12.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Kammaev, K. A. "Non-small cell lung carcinoma. Clinical case." Filin’s Clinical endoscopy 66, no. 3 (October 22, 2024): 62–65. http://dx.doi.org/10.31146/2415-7813-endo-66-3-62-65.

Der volle Inhalt der Quelle

Annotation:

In 2020, 2.2 million new cases of lung cancer were reported. The main form of lung cancer is non-small cell carcinoma (85%). Non-small cell lung cancer has 3 subtypes: adenocarcinoma, large cell and squamous cell carcinoma. Squamous cell lung cancer occurs in 20-40% of all lung cancers. Squamous cell lung cancer is associated with an unfavorable outcome. 5-year survival rate not exceeding 18%.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Kalemkerian, Gregory P., Wallace Akerley, Paul Bogner, Hossein Borghaei, Laura Chow, Robert J. Downey, Leena Gandhi, et al. "Small Cell Lung Cancer." Journal of the National Comprehensive Cancer Network 9, no. 10 (October 2011): 1086–113. http://dx.doi.org/10.6004/jnccn.2011.0092.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Kalemkerian, Gregory P., Wallace Akerley, Paul Bogner, Hossein Borghaei, Laura QM Chow, Robert J. Downey, Leena Gandhi, et al. "Small Cell Lung Cancer." Journal of the National Comprehensive Cancer Network 11, no. 1 (January 2013): 78–98. http://dx.doi.org/10.6004/jnccn.2013.0011.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Byrne, Bernadette. "Small cell lung cancer." Nursing Standard 8, no. 9 (November 23, 1993): 23–28. http://dx.doi.org/10.7748/ns.8.9.23.s42.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Hinson, J. A., and M. C. Perry. "Small cell lung cancer." CA: A Cancer Journal for Clinicians 43, no. 4 (July 1, 1993): 216–25. http://dx.doi.org/10.3322/canjclin.43.4.216.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

11

Bakhmutsky, Nicolay G., Vladimir A. Porkhanov, Vadim N. Bodnya, and Rostislav P. Schiryayev. "Small-cell lung cancer." Medical Herald of the South of Russia 8, no. 4 (January 1, 2017): 6–13. http://dx.doi.org/10.21886/2219-8075-2017-8-4-6-13.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

12

Sher, Taimur, Grace K. Dy, and Alex A. Adjei. "Small Cell Lung Cancer." Mayo Clinic Proceedings 83, no. 3 (March 2008): 355–67. http://dx.doi.org/10.4065/83.3.355.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

13

&NA;. "Small-Cell Lung Cancer." Oncology Times 26, no. 19 (October 2004): 23. http://dx.doi.org/10.1097/01.cot.0000292340.59988.2c.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

14

McVie, J. G., O. B. Dalesio, and H. van Tinteren. "Small Cell Lung Cancer." Acta Oncologica 28, no. 5 (January 1989): 729–41. http://dx.doi.org/10.3109/02841868909092304.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

15

Crompton, G. "Small cell lung cancer." BMJ 300, no. 6719 (January 27, 1990): 209–10. http://dx.doi.org/10.1136/bmj.300.6719.209.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

16

Sheppard, M. N. "Small cell lung cancer." BMJ 300, no. 6723 (February 24, 1990): 535. http://dx.doi.org/10.1136/bmj.300.6723.535-b.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

17

Rosti, G., G. Bevilacqua, P. Bidoli, L. Portalone, A. Santo, and G. Genestreti. "Small cell lung cancer." Annals of Oncology 17 (April 2006): ii5—ii10. http://dx.doi.org/10.1093/annonc/mdj910.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

18

&NA;. "Small cell lung cancer." Inpharma Weekly &NA;, no. 838 (May 1992): 10. http://dx.doi.org/10.2165/00128413-199208380-00015.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

19

Haque, Niaz, Amer Raza, Robin McGoey, Brian Boulmay, Lisa Diethelm, and Stephen Kantrow. "Small Cell Lung Cancer." Southern Medical Journal 105, no. 8 (August 2012): 418–23. http://dx.doi.org/10.1097/smj.0b013e3182601198.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

20

Eisen, Tim, Tamas Hickish, I. E. Smith, John Sloane, and Suzanne Eccles. "Small-cell lung cancer." Lancet 345, no. 8960 (May 1995): 1285–89. http://dx.doi.org/10.1016/s0140-6736(95)90930-3.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

21

Simon, George R., and Henry Wagner. "Small Cell Lung Cancer*." Chest 123, no. 1 (January 2003): 259S—271S. http://dx.doi.org/10.1378/chest.123.1_suppl.259s.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

22

Postmus, Pieter E. "Small-cell lung cancer." Lung Cancer 77 (June 2012): S19—S20. http://dx.doi.org/10.1016/j.lungcan.2012.05.098.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

23

Berendsen, H. H., L. de Leij, P. E. Postmus, S. Poppema, J. D. Elema, H. J. Sluiter, and T. H. The. "Small Cell Lung Cancer." Chest 91, no. 3 (March 1987): 11s—12s. http://dx.doi.org/10.1378/chest.91.3_supplement.11s.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

24

Ihde, D., B. Souhami, R. Comis, A. Gregor, H. Hansen, B. Johnson, N. Murray, et al. "Small cell lung cancer." Lung Cancer 17 (June 1997): S19—S21. http://dx.doi.org/10.1016/s0169-5002(97)00039-1.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

25

Jackman, David M., and Bruce E. Johnson. "Small-cell lung cancer." Lancet 366, no. 9494 (October 2005): 1385–96. http://dx.doi.org/10.1016/s0140-6736(05)67569-1.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

26

Ploner, F. "Small cell lung cancer." memo - Magazine of European Medical Oncology 1, no. 4 (December 2008): 243–45. http://dx.doi.org/10.1007/s12254-008-0067-5.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

27

Goodman, Gary R., and Robert B. Livingston. "Small cell lung cancer." Disease-a-Month 35, no. 12 (December 1989): 774–825. http://dx.doi.org/10.1016/0011-5029(89)90023-0.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

28

Livingston, Robert, and Gary E. Goodman. "Small cell lung cancer." Current Problems in Cancer 13, no. 1 (January 1989): 7–54. http://dx.doi.org/10.1016/0147-0272(89)90014-7.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

29

Leonard, RCF. "Small cell lung cancer." British Journal of Cancer 59, no. 4 (April 1989): 487–90. http://dx.doi.org/10.1038/bjc.1989.101.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

30

van Meerbeeck, Jan P., Dean A. Fennell, and Dirk KM De Ruysscher. "Small-cell lung cancer." Lancet 378, no. 9804 (November 2011): 1741–55. http://dx.doi.org/10.1016/s0140-6736(11)60165-7.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

31

Elias, Anthony D. "Small Cell Lung Cancer." Chest 112, no. 4 (October 1997): 251S—258S. http://dx.doi.org/10.1378/chest.112.4_supplement.251s.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

32

Kalemkerian, Gregory. "Small Cell Lung Cancer." Seminars in Respiratory and Critical Care Medicine 37, no. 05 (October 12, 2016): 783–96. http://dx.doi.org/10.1055/s-0036-1592116.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

33

O'Donnell, Walter J. "Small Cell Lung Cancer." Chest 107, no. 6 (June 1995): 241S—242S. http://dx.doi.org/10.1378/chest.107.6_supplement.241s.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

34

Ihde, Daniel C. "Small Cell Lung Cancer." Chest 107, no. 6 (June 1995): 243S—248S. http://dx.doi.org/10.1378/chest.107.6_supplement.243s.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

35

Simon, George, Robert J. Ginsberg, and John C. Ruckdeschel. "Small-Cell Lung Cancer." Chest Surgery Clinics of North America 11, no. 1 (February 2001): 165–88. https://doi.org/10.1016/s1052-3359(25)00558-7.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

36

Kurata, Takayasu, Isamu Okamoto, Kenji Tamura, and Masahiro Fukuoka. "Amrubicin for non-small-cell lung cancer and small-cell lung cancer." Investigational New Drugs 25, no. 5 (July 13, 2007): 499–504. http://dx.doi.org/10.1007/s10637-007-9069-0.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

37

Bhargav, Manjunath Hegde, Ganapati Hegde Mahesh, Channappagol Chetan, and P. Dayananda. "Review on Deep Learning Technique for Detecting Non-Small Cell Lung Cancer." Journal of Information Technology and Sciences 5, no. 3 (August 26, 2019): 15–20. https://doi.org/10.5281/zenodo.3377126.

Der volle Inhalt der Quelle

Annotation:

<em>The lung cancer is one of the major cancers in the world. Almost 80% of cancer we found in the world is related to lung only. We can find two different lung cancers; there are small cell lung cancer and non-small cell lung cancer. Here, we are only concentrated about the non-small cell lung cancer or (NSCLC). Here, we considered the KRAS mutation of the human gene. The KRAS biomarker is one of the main reasons for the NSCLC. Nearly 25% of the mutations happen in the form of KRAS mutation. Here, we have reviewed different deep learning and machine learning methods like convolutional neural network CNN,</em> <em>Support Vector Machine (SVM) and K Nearest Neighbors (KNN), to find the NSCLC. We can find different methods to compare the accuracy and precision of datasets. In this work, we tried to enhance the analysis gene for non-small cell lung cancer and detect the non-small cell lung using human genome sequence.</em>

APA, Harvard, Vancouver, ISO und andere Zitierweisen

38

Sankar, V., R. Kothai, and N. Vanisr. "Lung Cancer - A Review." International Journal of Health Sciences and Research 13, no. 10 (October 26, 2023): 307–15. http://dx.doi.org/10.52403/ijhsr.20231042.

Der volle Inhalt der Quelle

Annotation:

Lung cancer is the prime cause of cancer death among both men and women according to WHO report 2.09 million cases globally. It is also the chief cause of cancer death among men and the second leading cause of cancer death among women worldwide. The lung cancer classified into two different types are small-cell lung cancers (SCLC) and non-small-cell lung cancers (NSCLC). Non-small cell lung cancer is more common than small cell lung cancer. Treatment of lung cancer may involve a combination of surgery, chemotherapy, targeted therapy, immunotherapy, and radiation therapy. Therapeutic recommendations depend on several factors, including stage and type of cancer. Low- and middle-income countries now account for more than 50 % of lung cancer deaths each year the responses to current standard therapies are poor except for the most localized cancers. The purpose of this review is to sum up the types, epidemiology, detection, metastasis and the treatment of lung cancer. Key words: WHO, SCLC, NSCLC, Epidemiology, Metastasis

APA, Harvard, Vancouver, ISO und andere Zitierweisen

39

Kalkan, Fatih, and Mehmet Özler. "DELTA-9 TETRAHYDROCANNABINOID AND GEMSITABIN COMBINATION ON NON-SMALL CELL (SQUAMOUS CELL, SK-MES-1) LUNG CANCER CELL LINE." Era's Journal of Medical Research 10, no. 01 (June 2023): 1–12. http://dx.doi.org/10.24041/ejmr2023.1.

Der volle Inhalt der Quelle

Annotation:

Squamous cell carcinoma falls within the category of non-small cell lung cancers, presenting a considerable challenge in terms of treatment management. There has been growing interest in the potential anti-cancer properties of Delta-9 tetrahydrocannabinol. Gemcitabine, a nucleoside analog, has shown effectiveness against diverse cancer types. This study aimed to assess the combined efficacy of Delta-9 tetrahydrocannabinol and Gemcitabine in treating cancer. The squamous lung cancer cell line required for our study was provided by the stem cell unit. The doses were determined as 5µm/L and 10µm/L for Delta-9 tetrahydrocannabinol, 20 and 40 µm/Lfor Gemcitabine by performing a literature review. In our study, CellViabilityAnalysis by MTT, Xcelligence Real-Time Cell Analysis, Annexin V Apoptosis Flow Cytometry Analysis, Total Oxidant, Antioxidant Status, and Caspase-3 Detection Analysis was performed. Upon evaluating the rates of apoptotic cell death, it was observed that the THC 5 and THC 10 treatment groups exhibited a 30% and 60% increase, respectively, compared to the alcohol group. A significant difference in cytotoxic effect, as determined by MTT, was found between the control group and the Gemsitabin 20, Delta-9 Tetrahydrocannabinol 5µm/L, and Gemsitabin 20+Delta-9 Tetrahydrocannabinol 5µm/L groups (p<0.001). There was a statistically significant difference between the groups regarding TOS (p<0.001). All experimental groups exhibited a higher level of caspase 3 activations, in comparison to the control group. We observed a significant cytotoxic effect of Gemcitabine on squamous cell lung cancer cells. Delta-9 tetrahydrocannabinol, when used alone, exhibited a relatively low cytotoxic effect. However, no significant difference was observed in the groups where Delta-9 tetrahydrocannabinolwas combined with Gemcitabine.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

40

Nakanishi, Yoichi. "Chemotherapy for Lung Cancer (Small-cell Lung Cancer)." Haigan 56, no. 1 (2016): 43–47. http://dx.doi.org/10.2482/haigan.56.43.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

41

_, _. "Non–Small Cell Lung Cancer." Journal of the National Comprehensive Cancer Network 6, no. 3 (March 2008): 228. http://dx.doi.org/10.6004/jnccn.2008.0021.

Der volle Inhalt der Quelle

Annotation:

Lung cancer is the leading cause of cancer-related death in both men and women in the United States. An estimated 213,380 new cases (114,760 men and 98,620 women) of lung and bronchus cancer will be diagnosed in 2007, and 160,390 deaths (89,510 in men, 70,880 in women) are estimated to occur because of the disease. Non-small cell lung cancer (NSCLC) accounts for 80% to 85% of all lung cancer cases and includes 3 major types: (1) adenocarcinoma; (2) squamous cell (epidermoid) carcinoma; and (3) large-cell carcinoma. Adenocarcinoma is the most common type of lung cancer seen in the United States and is also the most frequently occurring cell type in nonsmokers. Important updates to the 2008 guidelines on NSCLC include the addition of tables on drugs and dosing information on chemotherapy regimens for adjuvant therapy. For the most recent version of the guidelines, please visit NCCN.org

APA, Harvard, Vancouver, ISO und andere Zitierweisen

42

End, A. "Diagnosis and treatment of lung cancer – Non-small cell lung cancer, small cell lung cancer and carcinoids." European Surgery 38, no. 1 (February 2006): 45–53. http://dx.doi.org/10.1007/s10353-006-0209-0.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

43

Ross, Mitchell D., Sreeja Biswas Roy, Pradnya D. Patil, Jasmine L. Huang, Nitika Thawani, Ralph Drosten, and Tanmay S. Panchabhai. "Coexistent Non–Small Cell Carcinoma and Small Cell Carcinoma in a Patient Presenting with Hyponatremia." Case Reports in Pulmonology 2018 (2018): 1–4. http://dx.doi.org/10.1155/2018/1718326.

Der volle Inhalt der Quelle

Annotation:

Despite recent advances in screening methods, lung cancer remains the leading cause of cancer-related deaths worldwide. By the time lung cancer becomes symptomatic and patients seek treatment, it is often too advanced for curative measures. Low-dose computed tomography (CT) screening has been shown to reduce mortality in patients at high risk of lung cancer. We present a 66-year-old man with a 50-pack-year smoking history who had a right upper lobe (RUL) pulmonary nodule and left lower lobe (LLL) consolidation on a screening CT. He reported a weight loss of 45 pounds over 3 months, had recently been hospitalized for hyponatremia, and was notably cachectic. A CT of the chest showed a stable LLL mass-like consolidation and a 9×21 mm subsolid lesion in the RUL. Navigational bronchoscopy biopsy of the RUL lesion revealed squamous non–small cell lung cancer (NSCLC). Endobronchial ultrasound-guided transbronchial needle aspiration of the LLL lesion revealed small cell lung cancer (SCLC). The final diagnosis was a right-sided Stage I NSCLC (squamous) and a left-sided limited SCLC. The RUL NSCLC was treated with stereotactic radiation; the LLL SCLC was treated with concurrent chemotherapy and radiation. In patients with multiple lung nodules, a diagnosis of synchronous multiple primary lung cancers (MPLCs) is crucial, as inadvertent upstaging of patients with MPLC (to T3 and/or T4 tumors) can lead to erroneous staging, inaccurate prognosis, and improper treatment. Recent advances in the diagnosis of small pulmonary nodules via navigational bronchoscopy and management of these lesions dramatically affect a patient’s overall prognosis.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

44

Skřičková, Jana, Bohdan Kadlec, and Ondřej Venclíček. "Non-small cell lung cancer." Vnitřní lékařství 63, no. 11 (November 1, 2017): 861–74. http://dx.doi.org/10.36290/vnl.2017.159.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

45

Ettinger, David S., Wallace Akerley, Gerold Bepler, Matthew G. Blum, Andrew Chang, Richard T. Cheney, Lucian R. Chirieac, et al. "Non–Small Cell Lung Cancer." Journal of the National Comprehensive Cancer Network 8, no. 7 (July 2010): 740–801. http://dx.doi.org/10.6004/jnccn.2010.0056.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

46

Ettinger, David S., Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, et al. "Non–Small Cell Lung Cancer." Journal of the National Comprehensive Cancer Network 10, no. 10 (October 2012): 1236–71. http://dx.doi.org/10.6004/jnccn.2012.0130.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

47

Susman, Ed. "Advanced Small-Cell Lung Cancer." Oncology Times 36, no. 20 (October 2014): 26. http://dx.doi.org/10.1097/01.cot.0000456288.49614.66.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

48

Armstrong, J., B. Shank, H. Scher, J. Gaynor, N. Martini, J. Kutcher, and M. Kris. "Limited Small-Cell Lung Cancer." American Journal of Clinical Oncology 14, no. 4 (August 1991): 285–90. http://dx.doi.org/10.1097/00000421-199108000-00003.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

49

Von Eyben, F. E. "Treating small cell lung cancer." BMJ 305, no. 6844 (July 4, 1992): 53. http://dx.doi.org/10.1136/bmj.305.6844.53.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

50

Fromer, Margot J. "Non-Small-Cell Lung Cancer." Oncology Times 30, no. 4 (February 2008): 21–25. http://dx.doi.org/10.1097/01.cot.0000313049.69678.f6.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!